Bupropion; Solriamfetol/MAO Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both medicines increase the amount of certain naturally occurring messengers (norepinephrine and dopamine) in the brain.
What might happen:
High norepinephrine and dopamine levels may cause changes in blood pressure as well as behavior or mood.
What you should do about this interaction:
Make sure your healthcare professional (e.g. doctor or pharmacist) knows that you are taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther 2012 Dec;92(6):771-7.
- 2.Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004 Sep;66(3):675-82.
- 3.Wellbutrin (bupropion hydrochloride) US prescribing information. GlaxoSmithKline November, 2019.
- 4.Sunosi (solriamfetol) US Prescribing Information. Jazz Pharmaceuticals, Inc. October, 2021.
- 5.Nardil (phenelzine sulfate) US prescribing information. Parke-Davis May, 2007.
- 6.USFood and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. available at: http://wayback.archive-it.org/7993/20170722185916/https://www.fda.gov/Drug s/DrugSafety/ucm263190.htm July 26, 2011.
- 7.USFood and Drug Administration. FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications. available at: http://www.fda.gov/Drugs/DrugSafety/ucm276119.htm October 21, 2011.
- 8.Surmaitis RM, Nappe TM, Cook MD. Serotonin syndrome associated with therapeutic metaxalone in a patient with cirrhosis. Am J Emerg Med 2016 Feb;34(2):346.e5-6.
- 9.Skelaxin (metaxalone) US prescribing information. Pfizer Laboratories Div Pfizer Inc. January, 2024.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.